Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 10/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16738809 | 0.90 | GAA (0.44) | GAAMCOLN3KDM1AHDAC9HTR2A | |
| SCHEMBL3841136 | 0.78 | GAA (0.46) | GAAMCOLN3AKR1B1KDM1AHTR2A | |
| SCHEMBL315669 | 0.78 | GAA (0.42) | GAAMCOLN3AKR1B1KDM1AHDAC9 | |
| SCHEMBL315173 | 0.78 | GAA (0.42) | GAAMCOLN3AKR1B1KDM1AHDAC9 | |
| SCHEMBL27688428 | 0.76 | GAA (0.44) | GAAMCOLN3AKR1B1KDM1AHTR2A | |
| SCHEMBL315713 | 0.76 | GAA (0.41) | GAAMCOLN3AKR1B1HDAC9HTR2A | |
| SCHEMBL316238 | 0.75 | GAA (0.42) | GAAMCOLN3AKR1B1KDM1AHTR2A | |
| SCHEMBL314642 | 0.74 | GAA (0.39) | GAAMCOLN3AKR1B1KDM1AHDAC9 | |
| SCHEMBL3844775 | 0.73 | HTR6 (0.39) | GAAMCOLN3AKR1B1KDM1AHTR2A | |
| SCHEMBL316500 | 0.73 | GAA (0.41) | GAAMCOLN3AKR1B1KDM1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7576103-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-08-18 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1831152-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1831189-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831152-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | disclosed |
| US-20060154965-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006066748-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF AS 5-HT ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066745-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | GAA 3526/4885MCOLN3 335/4885AKR1B1 950/4885 |
| US-20060154965-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | GAA 3526/4885MCOLN3 335/4885AKR1B1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.